Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Aly Diana A while ago, I discussed CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)—and honestly, the idea of editing genes still fascinates me. I remain deeply hopeful about what it could mean for the future of medicine. From time to time, I check on its progress, and I was delighted (even if a little
Read moreBy: Risky Dwi Rahayu Caffeine is one of the most widely used stimulants in the world. People usually consume it in coffee, tea, soft drinks, or chocolate, but it is also added to many sports‑nutrition products such as gels, chewing gum, energy shots, and energy drinks. Research shows that, when used correctly, caffeine can improve
Read moreBy: Rifaa’ah Rosyiidah, Adhella Menur Mental health significantly influences our well-being, productivity, relationships, and overall quality of life. As one of the leading causes of global disability, mental disorders have seen a substantial rise in prevalence, from 654.8 million cases in 1990 to 970.1 million in 2019, as per the 2019 Global Burden of Disease
Read moreBy: Aly Diana Anything quantum scares me—like, totally scares me. But lately, I’ve decided that it’s time to explore things that scare me and try to understand them, hoping they become less terrifying. Spoiler alert: it doesn’t make things any less scary. Instead, it turns into this wild ride of “scary but interesting.” So here
Read moreBy: Edrick Purnomo Putra Nowadays, difficulty in sleeping or sleeping disorders are highly prevalent, especially in adults. One of the most common types of sleeping disorders is insomnia, and it is estimated that one-third of the global population suffers from symptoms of insomnia. Insomnia is also more prevalent in older adults, females, and individuals with
Read moreBy: Restu Amalia Mukti, Adhella Menur Cervical cancer has a significant impact on women and families in Indonesia, with over 103 million women aged 15 and older at risk. It is the second most common cancer among women after breast cancer, with approximately 36,964 new cases diagnosed annually. Alarmingly, around 70% of cases are detected
Read moreBy: Erni, Adhella Menur The mumps outbreak in Indonesia The earliest description of mumps as a disease dates back to the 5th century BC by Hippocrates. One notable passage describes: “Swellings appeared about the ears, in many on either side, and in the greatest number on both sides. They were of a lax, large, diffused
Read moreBy: Aly Diana I have never considered myself a gamer, but I was thrilled to discover that a mini-game embedded in Borderlands 3 is reaching its audience—scientists and non-scientists alike—to advance science. This idea struck me as nothing short of brilliant: low cost, high yield, and impactful on a massive scale. During this discovery period,
Read moreBy: Adhella Menur As a member of the INA-RESPOND Science team, I am thrilled with the acceptance of the first publication from our HIV study, entitled “A Prospective Observational Cohort Study of HIV Infection in Indonesia: Baseline Characteristics and One-Year Mortality” in the BMC Infectious Dis-eases journal. This paper provides valuable evidence for Indonesia and
Read moreTo collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
